Health Management

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  Diabetes, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Ophthalmology,  Pulmonary, Urology, Additional Topics

Preventive Health & Lifestyle Medicine

Evolving Considerations in Adolescent and Adult Immunizations: Best Practices for Immunizing in a COVID-19 Environment

The world of immunizations in adolescents and adults has changed dramatically over the past 10 years. And now that is even more true with the COVID-19 pandemic of the last year. From newer vaccines to changing guidelines, the landscape has changed for payers, providers and patients. This two-part webinar series will take a close look at those changes on immunizations in adolescents and adults, and the affect that the COVID-19 pandemic is having on these immunizations. Attendees will be updated on the latest data and guidelines to help increase rates, costs and patient outcomes
Physician, Nursing and CMCN credits valid to August 1, 2023

Best Practices in Adolescent and Adult Immunizations: Managed Care Strategies for Immunizing in a COVID-19 Environment is a two-part webinar series

The world of immunizations in adolescents and adults has changed dramatically over the past 10 years. And now that is even more true with the COVID-19 pandemic of the last year. From newer vaccines to changing guidelines, the landscape has changed for payers, providers and patients. This two-part webinar series will take a close look at those changes on immunizations in adolescents and adults, and the affect that the COVID-19 pandemic is having on these immunizations. Attendees will be updated on the latest data and guidelines to help increase rates, costs and patient outcomes.
Physician, Nursing and CMCN credits valid to May 1, 2023

Recent Advances in the Treatment, Management and Prevention of Obesity

Obesity is a health care epidemic and one of the major drivers of health care costs in the United States. Excess adiposity affects most organ systems and obesity is linked to a wide range of comorbidities, including hypertension, type 2 diabetes, heart disease, and certain cancers. When aggregated across payers, obesity accounts for approximately 9.1% of total medical expenditures. Approximately 70% of adults in the US have obesity or are overweight. Obesity has been shown to be a risk factor for a number of fatal conditions, such as coronary heart disease, type 2 diabetes, hypertension, stroke, and certain types of cancer. Losing between 5% and 10% of body weight has been associated with a reduced risk of cardiovascular disease in obese or overweight adults. This activity will focus on the newest information on recent and upcoming medications for obesity to help improve patient education and lifestyle changes to reduce the risk of obesity and their associated comorbidities.
Physician, Nursing and CMCN credits valid to March 1, 2023

Recent Advances in the Treatment, Management and Prevention of Obesity

Obesity is a health care epidemic and one of the major drivers of health care costs in the United States. Excess adiposity affects most organ systems and obesity is linked to a wide range of comorbidities, including hypertension, type 2 diabetes, heart disease, and certain cancers. When aggregated across payers, obesity accounts for approximately 9.1% of total medical expenditures. Approximately 70% of adults in the US have obesity or are overweight. Obesity has been shown to be a risk factor for a number of fatal conditions, such as coronary heart disease, type 2 diabetes, hypertension, stroke, and certain types of cancer. Losing between 5% and 10% of body weight has been associated with a reduced risk of cardiovascular disease in obese or overweight adults. This activity will focus on the newest information on recent and upcoming medications for obesity to help improve patient education and lifestyle changes to reduce the risk of obesity and their associated comorbidities.
Physician, Nursing and CMCN credits valid to March 1, 2023

Best Practices in Adolescent and Adult Immunizations: Managed Care Strategies for Immunizing in a COVID-19 Environment

The world of immunizations in adolescents and adults has changed dramatically over the past 10 years. And now that is even more true with the COVID-19 pandemic of the last year. From newer vaccines to changing guidelines, the landscape has changed for payers, providers and patients. This two-part webinar series will take a close look at those changes on immunizations in adolescents and adults, and the affect that the COVID-19 pandemic is having on these immunizations. Attendees will be updated on the latest data and guidelines to help increase rates, costs and patient outcomes.
Physician, Nursing and CMCN credits valid to May 1, 2023

Addressing the Challenges of HPV Vaccination and Prevention of HPV-related Cancers in Young and Older Adults

Human papillomavirus (HPV) infection is the most common sexually transmitted infection in the United States, as well as a cause of various types of cancer. An estimated 79 million people in the United States are infected with some type of HPV, and approximately 50% of new infections occur in individuals before the age of 24. Despite the availability of safe and effective vaccines, HPV vaccination coverage remains low. There are various reasons why the vaccination rates are low, including patients’ and/or parents’ lack of knowledge about HPV and their discomfort with talking to health care providers about sexual activity, affordability, among other reasons.
Physician, Nursing and CMCN credits valid to October 1, 2022

Addressing the Challenges of HPV Vaccination and Prevention of HPV-related Cancers in Young and Older Adults

Human papillomavirus (HPV) infection is the most common sexually transmitted infection in the United States, as well as a cause of various types of cancer. An estimated 79 million people in the United States are infected with some type of HPV, and approximately 50% of new infections occur in individuals before the age of 24. Despite the availability of safe and effective vaccines, HPV vaccination coverage remains low. There are various reasons why the vaccination rates are low, including patients’ and/or parents’ lack of knowledge about HPV and their discomfort with talking to health care providers about sexual activity, affordability, among other reasons.
Physician, Nursing and CMCN credits valid to October 1, 2022

Addressing the Challenges of HPV Vaccination and Prevention of HPV-related Cancers: Managed Care Considerations and Updates

Human papillomavirus (HPV) infection is the most common sexually transmitted infection in the United States, as well as a cause of various types of cancer. An estimated 79 million people in the United States are infected with some type of HPV, and approximately 50% of new infections occur in individuals before the age of 24. Despite the availability of safe and effective vaccines, HPV vaccination coverage remains low. There are various reasons why the vaccination rates are low, including patients’ and/or parents’ lack of knowledge about HPV and their discomfort with talking to health care providers about sexual activity, affordability, among other reasons.
Physician, Nursing and CMCN credits valid to October 1, 2022

Behavioral Health

 

Chronic Illnesses

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  Diabetes, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Ophthalmology,  Pulmonary, Urology, Additional Topics

• Have increased knowledge regarding the
o Burden of adverse effects associated with anticholinergic therapy in patients with OAB
o Role of beta-3 adrenergic receptor agonists in the management of OAB
o Unmet needs surrounding the pharmacoeconomics of medications used to treat OAB
• Demonstrate greater confidence in their ability to
o Appropriately manage patients with OAB

AutoImmune

Improving the Treatment Outcomes in the Management of Psoriatic Arthritis

Psoriatic arthritis is a debilitating disease that may affect up to 1 million adults in the United States, affecting men and women equally. Psoriatic arthritis is a progressive, inflammatory disease that is associated with a number of dermatologic and musculoskeletal manifestations. Patients can experience extreme pain and joint damage that may affect their quality of life, physical function, and ability to work. Symptoms include fatigue, joint inflammation, and potentially progressive joint damage. This activity will examine the considerations for assessment, diagnosis, treatment and management of psoriatic arthritis.
Physician, Nursing and CMCN credits valid to August 1, 2023

Confronting the Clinical and Economic Burden of Atopic Dermatitis: Managed Care Considerations on the Role of New and Emerging Therapies

Atopic dermatitis is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Our improved understanding of the pathophysiology underlying atopic dermatitis is resulting in the development of targeted therapies for children and adult patients with this disease. There are approximately 17.8 million people with eczema or atopic dermatitis in the United States. Older treatments adequately care for patients with atopic dermatitis, but have shown problems with sustained efficacy in patients with eczema or atopic dermatitis. Fortunately for patients with this disease, several new treatments have recently become available, including JAK inhibitors, that have shown improved efficacy and safety, offering patients the potential for improved outcomes and quality of life. This activity will focus on new and emerging potential therapies, how clinicians can potentially integrate them into the treatment paradigm, what managed care professionals and payors need to know about these new options, and information on the mechanisms of action of these agents. With so many new options becoming potentially available in the management of atopic dermatitis, it is critical that physician medical directors, payers, pharmacy directors, pharmacists, nurse case managers and other HCPs are updated on the safety and efficacy data on these emerging options, possible strategies for implementing them into the treatment paradigm, and key points that managed care professionals need to know, which will ultimately improve patient outcomes.
Physician, Nursing and CMCN credits valid to August 1, 2023

Navigating an Increasingly Complex Treatment Paradigm in the Management of Hereditary Angioedema (HAE): Managed Care Considerations for Improved Patient Outcomes

Hereditary angioedema (HAE) is a rare autosomal dominant condition characterized by recurrent attacks of edema at different locations of the body. This potentially life-threatening disease affects approximately 1 in 67,000 individuals, with no identified differences in sex or ethnicity. HAE is characterized by recurrent edema attacks and the cutaneous attacks can be disabling, with the skin, gastrointestinal tract, and upper airways are most commonly affected and with a persistent risk to the patient of acute events of laryngeal swelling that may prove fatal if not treated in a timely manner. Angioedema in general can be confused with cellulitis, Graves disease, blepharochalasis, eosinophilic fasciitis, or amyloidosis which can lead to delays in diagnosis, and inappropriate treatment poses the risk of adverse events, unnecessary surgical interventions, a higher burden of misery, and a potentially higher rate of morbidity and mortality. Fortunately for patients with HAE, novel therapies have recently become available in the past year and a half that have shown improved efficacy and safety with improved administration methods, including oral therapy.
Physician, Nursing and CMCN credits valid to August 1, 2023

Clinical Management and Key Considerations to Target Optimal Treatment of Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is a chronic, frequently progressive condition that affects approximately 1.6 million people in the United States. This lifelong, systemic autoimmune illness often strikes patients at a young age and must be managed across a lifetime. According to the Crohn’s and Colitis Foundation of America, there are as many as 70,000 new cases diagnosed in a year. The diagnosis of IBD is most commonly based on imaging to assess the portions of the small bowel that are inaccessible to optical endoscopic visualization, which may also include a combination of endoscopy and histopathology. Imaging plays a critical role in the initial diagnosis and ongoing evaluation of IBD patients.
Physician, Nursing and CMCN credits valid to August 1, 2023

Recent Advances in Novel Biologics in the Management of Psoriatic Arthritis: Elevating the Standard of Care

Psoriatic arthritis is a debilitating disease that may affect up to 1 million adults in the United States, affecting men and women equally. Psoriatic arthritis is a progressive, inflammatory disease that is associated with a number of dermatologic and musculoskeletal manifestations. Patients can experience extreme pain and joint damage that may affect their quality of life, physical function, and ability to work. Symptoms include fatigue, joint inflammation, and potentially progressive joint damage. This activity will examine the considerations for assessment, diagnosis, treatment and management of psoriatic arthritis.
Physician, Nursing and CMCN credits valid to March 1, 2023

Preparing for a New Era in Alopecia Areata Management: Managed Care Considerations on the Role of New and Emerging Therapies is a three part webinar series

Alopecia areata is an autoimmune disease, characterized by hair loss, often patchy, on the scalp, face, or body. People suffering from alopecia areata experience symptoms when immune cells attack healthy hair follicles, causing the hair to fall out, often starting with smooth, round patches. More than half of patients with alopecia areata experience poor health-related quality of life and, as a result, the condition may lead to serious psychological consequences, including high levels of depression and anxiety. Fortunately for patients with this disease, several new treatments are currently undergoing late stage clinical trials, including JAK inhibitors and combinations, that have shown improved efficacy and safety.
Physician, Nursing and CMCN credits valid to April 1, 2023

A Closer Look at Emerging Therapies in the Management of Alopecia Areata: Managed Care Considerations on JAK Inhibitors in an Evolving Treatment Landscape

Alopecia areata is an autoimmune disease, characterized by hair loss, often patchy, on the scalp, face, or body. People suffering from alopecia areata experience symptoms when immune cells attack healthy hair follicles, causing the hair to fall out, often starting with smooth, round patches. More than half of patients with alopecia areata experience poor health-related quality of life and, as a result, the condition may lead to serious psychological consequences, including high levels of depression and anxiety. Fortunately for patients with this disease, several new treatments are currently undergoing late stage clinical trials, including JAK inhibitors and combinations, that have shown improved efficacy and safety.
Physician, Nursing and CMCN credits valid to April 1, 2023

Reducing the Economic Burden of Alopecia Areata: What Managed Care Needs to Know to About the Health Economics of a Changing Management Paradigm

Alopecia areata is an autoimmune disease, characterized by hair loss, often patchy, on the scalp, face, or body. People suffering from alopecia areata experience symptoms when immune cells attack healthy hair follicles, causing the hair to fall out, often starting with smooth, round patches. More than half of patients with alopecia areata experience poor health-related quality of life and, as a result, the condition may lead to serious psychological consequences, including high levels of depression and anxiety. Fortunately for patients with this disease, several new treatments are currently undergoing late stage clinical trials, including JAK inhibitors and combinations, that have shown improved efficacy and safety.
Physician, Nursing and CMCN credits valid to April 1, 2023

A Closer Look at the Clinical, Economic and Developmental Impact of Alopecia Areata: Strategies to Improve Patient Adherence, Quality of Life, and Costs

Alopecia areata is an autoimmune disease, characterized by hair loss, often patchy, on the scalp, face, or body. People suffering from alopecia areata experience symptoms when immune cells attack healthy hair follicles, causing the hair to fall out, often starting with smooth, round patches. More than half of patients with alopecia areata experience poor health-related quality of life and, as a result, the condition may lead to serious psychological consequences, including high levels of depression and anxiety. Fortunately for patients with this disease, several new treatments are currently undergoing late stage clinical trials, including JAK inhibitors and combinations, that have shown improved efficacy and safety.
Physician, Nursing and CMCN credits valid to April 1, 2023

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  Diabetes, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Ophthalmology,  Pulmonary, Urology , Additional Topics

Cardiovascular

The Latest Evidence on Emerging Therapies and Innovations in PAH Management

Pulmonary Arterial Hypertension (PAH) is a progressive vascular disorder characterized by vascular remodeling of the pulmonary arteries which carry blood from the heart to the lungs. For those with PAH, the muscles within the arterial walls tighten, which can cause thickening and/or scar tissue to develop, increasingly narrowing their diameter. This leads to a progressive increase in pulmonary vascular resistance that leads to right ventricular failure and significant morbidity and mortality. Over time, the heart muscle can become so weakened that its ability to pump enough blood through the body is lost, leading to heart failure. The estimated prevalence is between 15 and 50 cases per million individuals and about half of people diagnosed with PAH will not live past five years, while those with untreated PAH have an average survival expectancy of approximately three years following diagnosis – and even with aggressive management, PAH has a 15% annual mortality rate.

There continue to be significant challenges in identifying and diagnosing PAH because it requires a combination of information based on symptoms, a physician examination, risk factors, and other findings based on previous tests. Evaluation to detect the presence of PAH requires a comprehensive set of tests, which typically include laboratory testing, echocardiography, pulmonary function testing, assessment of exercise capacity with six-minute walk distance or cardiopulmonary exercising testing, imaging, nocturnal oximetry and/or overnight polysomnography, and right heart catheterization. These extensive tests are crucial in determining the severity of PAH and the appropriate treatment strategies for patients on an individual basis, driven by a provider’s knowledge of each patient’s specific needs.
Physician, Nursing and CMCN credits valid to August 1, 2023

New Developments in the Treatment and Management of Heart Failure: Managed Care Considerations on the Role of New and Emerging Therapies

Heart failure (HF) is a common condition that affects approximately 5.7 million people in the United States, and the prognosis for patients with heart failure has traditionally been poor. Projections show that by 2030, the prevalence of heart failure will increase 46 percent from recent estimates. HF is the reason for more than 1 million hospitalizations per year and an estimated $31 billion in costs in the U.S. each year. While recent efforts have focused on improving the outlook for patients with chronic heart failure, mortality and morbidity following admission for heart failure remain significant. Fortunately for patients with HF, new and emerging therapeutic options have entered the treatment paradigm recently, including SGLT2 inhibitors, showing the ability to improve clinical and economic outcomes for the patient and system, which makes it imperative to update medical directors, practicing physicians, nurses and other healthcare professionals on recent clinical data and recommendation updates regarding these new therapy options.
Physician, Nursing and CMCN credits valid to August 1, 2023

Recent Advances in the Treatment and Management of Heart Failure: Expert Perspectives on the Role of New and Emerging Therapies

Heart failure (HF) is a common condition that affects approximately 5.7 million people in the United States, and the prognosis for patients with heart failure has traditionally been poor. HF is the reason for more than 1 million hospitalizations per year and an estimated $31 billion in costs in the U.S. each year. While recent efforts have focused on improving the outlook for patients with chronic heart failure, mortality and morbidity following admission for heart failure remain significant. In recent decades, an improved understanding of the pathobiology of HF has led to the introduction of a number of new classes of medications that have improved the clinical outcomes of HF patients. However, despite these advances, nearly 6 million people in the United States have HF. The 5-year mortality rate for HF remains unacceptably high at about 50%, and 30-day HF patient readmissions are approximately 25%. Although multiple therapies have been shown to lower mortality in patients with HF, their applications in clinical practice have been less than ideal. Fortunately for patients with HF, new and emerging therapeutic options have entered the treatment paradigm recently, including SGLT2 inhibitors, showing the ability to reduce the risk of cardiovascular (CV) death or the worsening of heart failure in patients with heart failure both with and without type 2 diabetes.
Physician, Nursing and CMCN credits valid to March 1, 2023

New Frontiers in the Treatment and Management of Heart Failure: A Closer Look at the Role of Emerging Therapies is a two-part webinar series

Heart failure (HF) is a common condition that affects approximately 5.7 million people in the United States, and the prognosis for patients with heart failure has traditionally been poor. Projections show that by 2030, the prevalence of heart failure will increase 46 percent from recent estimates. HF is the reason for more than 1 million hospitalizations per year and an estimated $31 billion in costs in the U.S. each year. Fortunately for patients with HF, new and emerging therapeutic options have improved both clinical and economic outcomes for these patients and the system.
Physician, Nursing and CMCN credits valid to June 1, 2023

New Frontiers in the Treatment and Management of Heart Failure: A Closer Look at the Role of New Therapies

Heart failure (HF) is a common condition that affects approximately 5.7 million people in the United States, and the prognosis for patients with heart failure has traditionally been poor. Projections show that by 2030, the prevalence of heart failure will increase 46 percent from recent estimates. HF is the reason for more than 1 million hospitalizations per year and an estimated $31 billion in costs in the U.S. each year. Fortunately for patients with HF, new and emerging therapeutic options have improved both clinical and economic outcomes for these patients and the system.
Physician, Nursing and CMCN credits valid to June 1, 2023

Recent Advances in the Treatment and Management of Heart Failure: Managed Care Considerations on New and Emerging Therapies

Heart failure (HF) is a common condition that affects approximately 5.7 million people in the United States, and the prognosis for patients with heart failure has traditionally been poor. Projections show that by 2030, the prevalence of heart failure will increase 46 percent from recent estimates. HF is the reason for more than 1 million hospitalizations per year and an estimated $31 billion in costs in the U.S. each year. Fortunately for patients with HF, new and emerging therapeutic options have improved both clinical and economic outcomes for these patients and the system.
Physician, Nursing and CMCN credits valid to June 1, 2023

Multidisciplinary Approaches for Improving Patient Care in Pulmonary Arterial Hypertension: Advances in Therapeutic Selection

Pulmonary Arterial Hypertension (PAH) is a progressive vascular disorder characterized by vascular remodeling of the pulmonary arteries which carry blood from the heart to the lungs. For those with PAH, the muscles within the arterial walls tighten, which often leads to a progressive increase in pulmonary vascular resistance that leads to right ventricular failure and significant morbidity and mortality. Over time, the heart muscle can become so weakened that its ability to pump enough blood through the body is lost, leading to heart failure. About half of people diagnosed with PAH will not live past five years, while those with untreated PAH have an average survival expectancy of approximately three years following diagnosis. There continue to be significant challenges in identifying and diagnosing PAH because it requires a combination of information based on symptoms, a physician examination, risk factors, and other findings based on previous tests. Evaluation typically include laboratory testing, echocardiography, pulmonary function testing, assessment of exercise capacity with six-minute walk distance or cardiopulmonary exercising testing, imaging, and a right heart catheterization among others.

The American College of Chest Physicians (ACCP) also published new treatment guidelines in 2019. There are a wide variety of treatment options to help manage PAH, including general measures, nonspecific pharmacologic intervention and targeted pharmacologic intervention. These include monotherapy and combination therapies that can include prostacyclin/prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors. Physicians must be able to make tailored treatment decisions for individual patients, based on their diagnosis and severity, for proper management. Optimal treatment, accurate classification, and risk stratification are keys to managing the patient’s health and costs, as incorrect classification can lead to inappropriate treatment decisions. The current guidance recommendations suggest that the optimal therapeutic approach for each patient must be personalized to take into account a patient’s severity, route of administration of therapy, adverse effect profiles, comorbidity, and achieving treatment goals. As such, patients require access to all indicated treatment options to optimize disease management.
Physician, Nursing and CMCN credits valid to March 1, 2023

Therapeutic Advances in the Management of Hyperkalemia with End Stage Renal Disease: Improving Clinical and Cost Outcomes in an Evolving Treatment Paradigm

Hyperkalemia, also known has high potassium, is an elevated level of potassium in the blood. Typically this results in no symptoms, but occasionally when severe it results in palpitations, muscle pain, muscle weakness, or numbness. Decreased kidney function is a major cause of hyperkalemia, especially in chronic kidney disease (CKD). Hyperkalemia occurs in up to 10% of hospitalized patients and is associated increased morbidity if left unaddressed. Fortunately for patients who experience hyperkalemia, new therapies have become available in recent years that have shown improved efficacy and safety. Attendees will be updated on these novel options and how they can integrate them into the treatment paradigm and optimize costs.
Physician, Nursing and CMCN credits valid to November 1, 2022

A Deeper Look into Novel Potassium Binders in the Management of Hyperkalemia with End Stage Renal Disease: Individualizing Treatment for Improved Clinical and Cost Outcomes

Hyperkalemia, also known has high potassium, is an elevated level of potassium in the blood. Typically this results in no symptoms, but occasionally when severe it results in palpitations, muscle pain, muscle weakness, or numbness. Decreased kidney function is a major cause of hyperkalemia, especially in chronic kidney disease (CKD). Hyperkalemia occurs in up to 10% of hospitalized patients and is associated increased morbidity if left unaddressed. Fortunately for patients who experience hyperkalemia, new therapies have become available in recent years that have shown improved efficacy and safety. Attendees will be updated on these novel options and how they can integrate them into the treatment paradigm and optimize costs.
Physician, Nursing and CMCN credits valid to November 1, 2022

Comparative Effectiveness and Coordinated Care in Hyperkalemia with End Stage Renal Disease: What Does Managed Care Need to Know about Newer Therapies?

Hyperkalemia, also known has high potassium, is an elevated level of potassium in the blood. Typically this results in no symptoms, but occasionally when severe it results in palpitations, muscle pain, muscle weakness, or numbness. Decreased kidney function is a major cause of hyperkalemia, especially in chronic kidney disease (CKD). Hyperkalemia occurs in up to 10% of hospitalized patients and is associated increased morbidity if left unaddressed. Fortunately for patients who experience hyperkalemia, new therapies have become available in recent years that have shown improved efficacy and safety. Attendees will be updated on these novel options and how they can integrate them into the treatment paradigm and optimize costs.
Physician, Nursing and CMCN credits valid to November 1, 2022

Improving Patient Adherence and Quality of Life Hyperkalemia with ESRD: Strategies for Detecting and Managing Adverse Events with Novel Therapies

Hyperkalemia, also known has high potassium, is an elevated level of potassium in the blood. Typically this results in no symptoms, but occasionally when severe it results in palpitations, muscle pain, muscle weakness, or numbness. Decreased kidney function is a major cause of hyperkalemia, especially in chronic kidney disease (CKD). Hyperkalemia occurs in up to 10% of hospitalized patients and is associated increased morbidity if left unaddressed. Fortunately for patients who experience hyperkalemia, new therapies have become available in recent years that have shown improved efficacy and safety. Attendees will be updated on these novel options and how they can integrate them into the treatment paradigm and optimize costs.
Physician, Nursing and CMCN credits valid to November 1, 2022

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  Diabetes, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Ophthalmology,  Pulmonary, Urology , Additional Topics

Diabetes

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  Diabetes, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Ophthalmology,  Pulmonary, Urology , Additional Topics

Infectious Disease

Patient-Focused Treatment Decisions in the Management of HIV: Individualizing ART Decision Making for Improved Clinical and Economic Outcomes

The human immunodeficiency virus (HIV) is a lentivirus that causes HIV infection and over time acquired
immunodeficiency syndrome (AIDS). AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. HIV infects vital cells in the human immune system such as helper T cells, macrophages, and dendritic cells. HIV infection leads to low levels of CD4+T cells through a number of specific mechanisms. When CD4+ T cell numbers decline below a critical level, cell mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections. The CDC estimates that 1,218,400 persons in the United States aged 13 years and older are living with HIV infection. Additionally, an estimated 6,955 people died from HIV and AIDS in 2018. Fortunately for patients with HIV, several new therapies have become available over the past few years, and more are set to become available soon. This activity is designed to address the challenge of individualizing HIV care with current treatment guidelines and recent clinical data, emerging therapy options and combinations, strategies for newly diagnosed patients and strategies for switching therapy for virally-suppressed patients, identifying patients who would benefit from treatment alteration, the role of newer combination regimens, cost optimization for HIV therapies, emerging therapies for heavily treatment-experienced adults, patient adherence strategies, and then explain how to apply them to the optimal care of a wide variety of HIV patients.
Physician, Nursing and CMCN credits valid to August 1, 2023

Evolving Considerations in the Treatment and Management of HIV: Expert Strategies on Navigating ART Decisions for Optimized Clinical and Economic Outcomes

The human immunodeficiency virus (HIV) is a lentivirus that causes HIV infection and over time acquired
immunodeficiency syndrome (AIDS). AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. HIV infects vital cells in the human immune system such as helper T cells, macrophages, and dendritic cells. HIV infection leads to low levels of CD4+T cells through a number of specific mechanisms. When CD4+ T cell numbers decline below a critical level, cell mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections. The CDC estimates that 1,218,400 persons in the United States aged 13 years and older are living with HIV infection. Additionally, an estimated 6,955 people died from HIV and AIDS in 2018. Fortunately for patients with HIV, several new therapies have become available over the past few years, and more are set to become available soon. This activity is designed to address the challenge of individualizing HIV care with current treatment guidelines and recent clinical data, emerging therapy options and combinations, strategies for newly diagnosed patients and strategies for switching therapy for virally-suppressed patients, identifying patients who would benefit from treatment alteration, the role of newer combination regimens, cost optimization for HIV therapies, emerging therapies for heavily treatment-experienced adults, patient adherence strategies, and then explain how to apply them to the optimal care of a wide variety of HIV patients.
Physician, Nursing and CMCN credits valid to March 1, 2023

Managing the Cost of C. difficile Infection with Novel Therapies: Best Practices in Managed Care for Improved Clinical and Economic Outcomes

The epidemiology and incidence of hospital- and community-acquired Clostridium difficile infection (CDI) has changed over the past decade resulting in increased cases of initial and recurrent infection. Up to 25% of patients with an initial episode of CDI experience disease recurrence. Recurrent CDI is particularly challenging to manage.

This webcast series will provide education on reducing the risk of recurrence, patient-specific risk factors for recurrent CDI, recommended and emerging treatments for recurrent CDI, and managed care considerations around the prevention and management of rCDI.
Physician, Nursing and CMCN credits valid to November 1, 2023

A Closer Look at the Prevention and Management of C. difficile Infection and Recurrence: Expert Perspectives for Improved Clinical and Economic Outcomes

The epidemiology and incidence of hospital- and community-acquired Clostridium difficile infection (CDI) has changed over the past decade resulting in increased cases of initial and recurrent infection. Up to 25% of patients with an initial episode of CDI experience disease recurrence. Recurrent CDI is particularly challenging to manage.

This webcast series will provide education on reducing the risk of recurrence, patient-specific risk factors for recurrent CDI, recommended and emerging treatments for recurrent CDI, and managed care considerations around the prevention and management of rCDI.
Physician, Nursing and CMCN credits valid to November 1, 2023

Managing the Cost of C. difficile Infection and Recurrence with Novel Therapies: Best Practices in Managed Care for Improved Clinical and Economic Outcomes

The epidemiology and incidence of hospital- and community-acquired Clostridium difficile infection (CDI) has changed over the past decade resulting in increased cases of initial and recurrent infection. Up to 25% of patients with an initial episode of CDI experience disease recurrence. Recurrent CDI is particularly challenging to manage.

This webcast series will provide education on reducing the risk of recurrence, patient-specific risk factors for recurrent CDI, recommended and emerging treatments for recurrent CDI, and managed care considerations around the prevention and management of rCDI.
Physician, Nursing and CMCN credits valid to November 1, 2023

A New Era in the Prevention and Management of CMV Infection

Cytomegalovirus (CMV) infection remains a frequent complication in hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT) recipients. In addition to causing a variety of end-organ diseases, CMV infection is also associated with rejection after SOT and with graft versus host disease (GVHD) after HSCT. Antiviral prophylaxis is effective against direct and indirect effects of CMV infection. Preemptive therapy, more commonly used after HSCT, is based on surveillance, and targets therapy to patients at highest risk. Novel antiviral therapies with different mechanisms of action have recently become available giving healthcare professionals new options in the management of this infection. This program will take a look at those advances and provide up to date strategies for the management of CMV infection.

This webinar series on the evolving role of novel therapies in CMV infection management will take a close look at recent guideline updates, clinical data, and strategies for the prevention and management of CMV.
Physician, Nursing and CMCN credits valid to September 1, 2023

Recent Advances in the Prevention and Management of Cytomegalovirus (CMV) Infection in Transplant Recipients: Managed Care Considerations for Improved Outcomes

Cytomegalovirus (CMV) infection remains a frequent complication in hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT) recipients. In addition to causing a variety of end-organ diseases, CMV infection is also associated with rejection after SOT and with graft versus host disease (GVHD) after HSCT. Antiviral prophylaxis is effective against direct and indirect effects of CMV infection. Preemptive therapy, more commonly used after HSCT, is based on surveillance, and targets therapy to patients at highest risk. Novel antiviral therapies with different mechanisms of action have recently become available giving healthcare professionals new options in the management of this infection. This program will take a look at those advances and provide up to date strategies for the management of CMV infection.

This webinar series on the evolving role of novel therapies in CMV infection management will take a close look at recent guideline updates, clinical data, and strategies for the prevention and management of CMV.
Physician, Nursing and CMCN credits valid to September 1, 2023

A New Era in the Prevention and Management of Cytomegalovirus (CMV) Infection in Transplant Recipients: Assessing the Evidence in Real-World Applications

Cytomegalovirus (CMV) infection remains a frequent complication in hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT) recipients. In addition to causing a variety of end-organ diseases, CMV infection is also associated with rejection after SOT and with graft versus host disease (GVHD) after HSCT. Antiviral prophylaxis is effective against direct and indirect effects of CMV infection. Preemptive therapy, more commonly used after HSCT, is based on surveillance, and targets therapy to patients at highest risk. Novel antiviral therapies with different mechanisms of action have recently become available giving healthcare professionals new options in the management of this infection. This program will take a look at those advances and provide up to date strategies for the management of CMV infection.

This webinar series on the evolving role of novel therapies in CMV infection management will take a close look at recent guideline updates, clinical data, and strategies for the prevention and management of CMV.
Physician, Nursing and CMCN credits valid to September 1, 2023

Novel Treatment Advances and Approaches in Management of HIV

HIV is a lentivirus that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). HIV infection leads to low levels of CD4+ T cells through a number of specific mechanisms. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections. The CDC estimates that 1,218,400 people in the US aged 13 years and older are living with HIV infection and an estimated 6,955 people died in 2019. Fortunately, several new therapies have become available recently, and more are set to become available soon.
Physician, Nursing and CMCN credits valid to January 1, 2023

Integrating the Latest Data and Guidelines in the Management of HIV: Strategies for Optimizing Clinical and Economic Outcomes

HIV is a lentivirus that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). HIV infection leads to low levels of CD4+ T cells through a number of specific mechanisms. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections. The CDC estimates that 1,218,400 people in the US aged 13 years and older are living with HIV infection and an estimated 6,955 people died in 2019. Fortunately, several new therapies have become available recently, and more are set to become available soon.
Physician, Nursing and CMCN credits valid to January 1, 2023

Improving Patient Adherence and Quality of Life in HIV: A Closer Look at the Role of Novel Long-Acting Injectable and Implantable ART Formulations

HIV is a lentivirus that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). HIV infection leads to low levels of CD4+ T cells through a number of specific mechanisms. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections. The CDC estimates that 1,218,400 people in the US aged 13 years and older are living with HIV infection and an estimated 6,955 people died in 2019. Fortunately, several new therapies have become available recently, and more are set to become available soon.
Physician, Nursing and CMCN credits valid to January 1, 2023

Comparative Effectiveness and Payer-Provider Coordination in HIV: What Does Managed Care Need to Know About New and Emerging Therapies?

HIV is a lentivirus that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). HIV infection leads to low levels of CD4+ T cells through a number of specific mechanisms. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections. The CDC estimates that 1,218,400 people in the US aged 13 years and older are living with HIV infection and an estimated 6,955 people died in 2019. Fortunately, several new therapies have become available recently, and more are set to become available soon.
Physician, Nursing and CMCN credits valid to January 1, 2023

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  Diabetes, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Ophthalmology,  Pulmonary, Urology , Additional Topics

Musculoskeletal & Rheumatology

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  Diabetes, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Ophthalmology,  Pulmonary, Urology ,

Neurological

Optimizing Management Decisions in Insomnia: Evidence-based Treatments to Improve Outcomes

Insomnia is a sleep disorder which makes it difficult to fall asleep or stay asleep, even when a person has the chance to do so. This can affect a person’s sleep so much that they still feel tired after they wake up. Insomnia can also make patients feel that they are the only one still awake while the rest of the world sleeps. It can sap your energy level, affects your mood, and causes stress with your health, work performance and quality of life. The dangers of insomnia can affect more than just a person’s mood and if not treated properly can lead to other effects such as anxiety, depression, irritability, concentration problems, memory problems, poor immune system function, and reduced reaction time. Many adults experience acute insomnia, which can last for days or weeks and is usually the result of stress or a traumatic event in one’s life. There are some people that experience chronic insomnia which is long term and can lasts for a month or more. There are 60 million Americans affected by the disease. About 25% of Americans experience acute insomnia each year with around 10% experiencing chronic insomnia.
Physician, Nursing and CMCN credits valid to August 1, 2023

New Evidence in Excessive Daytime Sleepiness Management: Meeting the Challenge to Provide Optimal Treatment

Excessive daytime sleepiness (EDS) is a common complaint in individuals with obstructive sleep apnea (OSA) and narcolepsy. Consequences of EDS include decreased cognitive functioning, work productivity, and quality of life, and increased risk for occupational and motor vehicle accidents. When factors such as treatment adherence, medications, comorbid illness, and inadequate sleep duration are controlled for, EDS is still reported in up to 6% to 18% of people treated for sleep disorders, with EDS being a persistent symptom. For most people, mild sleepiness is apparent only during boring, sedentary situations, however patients with narcolepsy, severe EDS, lead to involuntary somnolence during regular activities that could put the patient and others in a harmful situation, such as driving, eating, or talking.

Narcolepsy and OSA can interfere with psychological, social, and cognitive function and development and can inhibit academic, work, and social activities. With the potential danger surrounding narcoleptic patients, it is important for clinicians to understand and identify major sleep disorders and the best methods to diagnose and treat them. Greater awareness of sleep disorders and its symptoms can help accurately and efficiently diagnosis the disease. As research continues to grow, better treatments for narcolepsy are becoming available. Sleep studies are an essential part of the evaluation and diagnosis of patients with narcolepsy. While in most instances imaging studies do not give an accurate picture of what is going on, a few studies done with an MRI can show structural abnormalities of the brain that will help show what may be the underlying cause of the sleep disorder. Symptoms can include EDS, sleep paralysis, hallucinations, but cataplexy is the most specific symptom and occurs in almost no other diseases. The combination of an overnight polysomnogram (PSG) followed by a multiple sleep latency test (MSLT) can provide the proper evidence of narcolepsy while excluding other sleep disorders.
Physician, Nursing and CMCN credits valid to June 1, 2023

Best Practices in the Management of Multiple Sclerosis: Optimizing Clinical and Economic Outcomes in an Evolving Treatment Paradigm

Multiple Sclerosis (MS) is a chronic progressive disease. It is the most common neurological cause of disability among young adults, with a prevalence of approximately 400,000 cases throughout the United States, and every week around 200 people are diagnosed with the disease. Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. A number of factors must be considered when selecting a treatment regimen for patients with MS, including variations in clinical and MRI evidence of disease. Over the past decade, there have been numerous revisions to MS diagnostic criteria and the development of multiple new and emerging therapies. While the explosion of these emerging therapies have shown the ability to improve outcomes and quality of life in patient’s MS, it makes staying current with best practices a challenge that must be overcome through education. New options showing improved efficacy, safety and deliverability have recently been approved, which will change the treatment paradigm, and it is for this reason that medical directors, practicing physicians, nurse case managers and other healthcare professionals must be updated on emerging treatments and strategies in the management of relapsing MS.
Physician, Nursing and CMCN credits valid to June 1, 2023

Evolving Considerations in the Treatment and Management of Amyotrophic Lateral Sclerosis (ALS): Optimizing Strategies for Slowing Disease Progression

Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig’s disease, is a progressive
neurodegenerative disease that affects nerve cells in the brain and the spinal cord. An estimated 20,000 people in the United States are living with ALS. It is a progressive disease in which the motor neurons eventually die. Mortality is usually the result of respiratory failure. Although most patients with ALS die within 3 to 5 years after symptoms first appear, about 20% of patients with ALS will live 5 years, 10% will live 10 years, and about 5% will live 20 years or more. Currently, there is no cure for ALS. Fortunately for patients with ALS, the treatment paradigm has expanded in recent years, giving medical directors and clinicians many more options in managing symptoms and delaying progression in the ALS patient population. This activity will feature strategies to overcome challenges in the optimal treatment of ALS and highlight the role of managed care professionals in making informed decisions on therapies that will improve quality of life, slow the disease progression, and minimize costs.
Physician, Nursing and CMCN credits valid to March 1, 2023

Patient-Focused Treatment Decisions in the Management of Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic progressive disease. It is the most common neurological cause of disability among young adults, with a prevalence of approximately 1 million cases throughout the United States, and every week around 200 people are diagnosed with the disease. Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. A number of factors must be considered when selecting a treatment regimen for patients with MS, including variations in clinical and MRI evidence of disease. Over the past decade, there have been numerous revisions to MS diagnostic criteria and the development of multiple new and emerging therapies. While the explosion of these emerging therapies have shown the ability to improve outcomes and quality of life in patient’s MS, it makes staying current with best practices a challenge that must be overcome through education.
Physician, Nursing and CMCN credits valid to March 1, 2023

New Developments in the Treatment and Management of Chronic Cough: Managed Care Considerations on the Role of New and Emerging Therapies

Chronic cough, which is observed in approximately 12% of the US population, is defined as a cough that lasts for more than 8 weeks. Patients with chronic cough are often distressed by the condition, which can lead to depression, anxiety, a decline in quality of life, and changes to their social activities. The diagnosis and management of chronic cough can be challenging, with only approximately 50% of patients receiving a diagnosis. Recent advances have been made in the understanding and management of refractory chronic cough, with several novel therapies being evaluated in ongoing clinical studies.
Physician, Nursing and CMCN credits valid to March 1, 2023

Diagnosing and Treating Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea

Narcolepsy and OSA can interfere with psychological, social, and cognitive function and development and can inhibit academic, work, and social activities. With the potential danger surrounding narcoleptic patients, it is important for clinicians to understand and identify major sleep disorders and the best methods to diagnose and treat them. Greater awareness of sleep disorders and its symptoms can help accurately and efficiently diagnosis the disease. As research continues to grow, better treatments for narcolepsy are becoming available. Sleep studies are an essential part of the evaluation and diagnosis of patients with narcolepsy. While in most instances imaging studies do not give an accurate picture of what is going on, a few studies done with an MRI can show structural abnormalities of the brain that will help show what may be the underlying cause of the sleep disorder. Symptoms can include EDS, sleep paralysis, hallucinations, but cataplexy is the most specific symptom and occurs in almost no other diseases. The combination of an overnight polysomnogram (PSG) followed by a multiple sleep latency test (MSLT) can provide the proper evidence of narcolepsy while excluding other sleep disorders. This activity will focus on an understanding of novel therapies for EDS in OSA and narcolepsy and how to incorporate this evidence into optimal treatment planning to reduce the burden of EDS. With recent evidence and data are showing a lot of promise, there needs to be more education on the best treatment strategies available. By navigating recent clinical trial data on these therapies, the attendees should be better able to apply the latest evidence to practice, optimizing the management of EDS in patients with narcolepsy and OSA. Given the limitations in safety and efficacy of more traditional therapies for EDS, there is a need for novel therapies and the best methods to manage them.
Physician, Nursing and CMCN credits valid to March 1, 2023

Managing Clinical and Cost Outcomes in Multiple Sclerosis: Utilizing Data to Make Informed Decisions in Managed Care

Multiple Sclerosis (MS) is a chronic progressive disease. It is the most common neurological cause of disability among young adults, with a prevalence of approximately one million cases throughout the United States. Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. Effective and timely treatment of MS can greatly improve the quality of life in MS patients. With the advancement and complexity of different treatment options, including therapies that have recently become available, managed care professionals are being challenged to make informed decisions in their organizations and provide the correct treatment options that are available to patients.
Physician, Nursing and CMCN credits valid to January 1, 2023

A Closer Look into the Latest Data in the Treatment of Multiple Sclerosis: Utilizing Recent Evidence to Make Informed Decisions

Multiple Sclerosis (MS) is a chronic progressive disease. It is the most common neurological cause of disability among young adults, with a prevalence of approximately one million cases throughout the United States. Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. Effective and timely treatment of MS can greatly improve the quality of life in MS patients. With the advancement and complexity of different treatment options, including therapies that have recently become available, managed care professionals are being challenged to make informed decisions in their organizations and provide the correct treatment options that are available to patients.
Physician, Nursing and CMCN credits valid to January 1, 2023

Comparative Effectiveness and Payer-Provider Coordination in Multiple Sclerosis: What Does Managed Care Need to Know About New and Emerging Therapeutics?

Multiple Sclerosis (MS) is a chronic progressive disease. It is the most common neurological cause of disability among young adults, with a prevalence of approximately one million cases throughout the United States. Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. Effective and timely treatment of MS can greatly improve the quality of life in MS patients. With the advancement and complexity of different treatment options, including therapies that have recently become available, managed care professionals are being challenged to make informed decisions in their organizations and provide the correct treatment options that are available to patients.
Physician, Nursing and CMCN credits valid to January 1, 2023

Improving Patient Adherence and Quality of Life in Multiple Sclerosis: Strategies for Managing Adverse Events Associated with New and Emerging Therapies

Multiple Sclerosis (MS) is a chronic progressive disease. It is the most common neurological cause of disability among young adults, with a prevalence of approximately one million cases throughout the United States. Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. Effective and timely treatment of MS can greatly improve the quality of life in MS patients. With the advancement and complexity of different treatment options, including therapies that have recently become available, managed care professionals are being challenged to make informed decisions in their organizations and provide the correct treatment options that are available to patients.
Physician, Nursing and CMCN credits valid to January 1, 2023

New Frontiers in the Treatment and Management of Alzheimer’s Disease (AD): What Managed Care Needs to Know about New and Emerging Therapies

Alzheimer’s disease is the most common form of dementia, affecting an estimated 5 million people in the United States. It is a cognitive disorder that includes behavioral impairment that interferes with social and occupational functioning. Alzheimer’s disease care costs $172 billion annually in the US alone. Fortunately for patients with Alzheimer’s disease, new and emerging therapies, including anti-beta-amyloid (Aß) monoclonal antibodies, are undergoing late stage clinical trials or have been submitted for regulatory review. This program will provide strategies to overcome challenges in the optimal treatment and management of Alzheimer’s disease and highlight the role of managed care professionals in making informed decisions on these new and emerging therapies that will improve quality of life, significantly reduce clinical decline, and minimize costs throughout the healthcare system.
Physician, Nursing and CMCN credits valid to December 1, 2022

Benefit Design and Coordinated Care in Alzheimer’s Disease (AD): What Managed Care Needs to Know about Emerging Therapies and Reducing Clinical Decline

Alzheimer’s disease is the most common form of dementia, affecting an estimated 5 million people in the United States. It is a cognitive disorder that includes behavioral impairment that interferes with social and occupational functioning. Alzheimer’s disease care costs $172 billion annually in the US alone. Fortunately for patients with Alzheimer’s disease, new and emerging therapies, including anti-beta-amyloid (Aß) monoclonal antibodies, are undergoing late stage clinical trials or have been submitted for regulatory review. This program will provide strategies to overcome challenges in the optimal treatment and management of Alzheimer’s disease and highlight the role of managed care professionals in making informed decisions on these new and emerging therapies that will improve quality of life, significantly reduce clinical decline, and minimize costs throughout the healthcare system.
Physician, Nursing and CMCN credits valid to December 1, 2022

Improving Patient Adherence and Quality of Life in Alzheimer’s Disease (AD): Optimizing Adverse Event Management and Imaging for Emerging Therapies

Alzheimer’s disease is the most common form of dementia, affecting an estimated 5 million people in the United States. It is a cognitive disorder that includes behavioral impairment that interferes with social and occupational functioning. Alzheimer’s disease care costs $172 billion annually in the US alone. Fortunately for patients with Alzheimer’s disease, new and emerging therapies, including anti-beta-amyloid (Aß) monoclonal antibodies, are undergoing late stage clinical trials or have been submitted for regulatory review. This program will provide strategies to overcome challenges in the optimal treatment and management of Alzheimer’s disease and highlight the role of managed care professionals in making informed decisions on these new and emerging therapies that will improve quality of life, significantly reduce clinical decline, and minimize costs throughout the healthcare system.
Physician, Nursing and CMCN credits valid to December 1, 2022

A Deeper Look into Emerging Therapies in the Management of Alzheimer’s Disease (AD): What Does Recent Clinical Trial Data Have to Say?

Alzheimer’s disease is the most common form of dementia, affecting an estimated 5 million people in the United States. It is a cognitive disorder that includes behavioral impairment that interferes with social and occupational functioning. Alzheimer’s disease care costs $172 billion annually in the US alone. Fortunately for patients with Alzheimer’s disease, new and emerging therapies, including anti-beta-amyloid (Aß) monoclonal antibodies, are undergoing late stage clinical trials or have been submitted for regulatory review. This program will provide strategies to overcome challenges in the optimal treatment and management of Alzheimer’s disease and highlight the role of managed care professionals in making informed decisions on these new and emerging therapies that will improve quality of life, significantly reduce clinical decline, and minimize costs throughout the healthcare system.
Physician, Nursing and CMCN credits valid to December 1, 2022

Novel Treatment Advances and Approaches in the Management of Insomnia: Managed Care Considerations in an Evolving Management Paradigm

Insomnia is a sleep disorder which makes it difficult to fall asleep or stay asleep, even when a person has the chance to do so. This can affect a person’s sleep so much that they still feel tired after they wake up. The dangers of insomnia can affect more than just a person’s mood as people and if not treated properly can lead to other effects such as anxiety, depression, irritability, concentration problems, memory problems, poor immune system function, and reduced reaction time. There are 60 million Americans affected by the disease. About 25% of Americans experience acute insomnia each year with around 10% experiencing chronic insomnia.
Physician, Nursing and CMCN credits valid to December 1, 2022

Integrating the Latest Data and Guidelines in the Management of Insomnia: Utilizing New Therapies for Optimal Clinical and Economic Outcomes

Insomnia is a sleep disorder which makes it difficult to fall asleep or stay asleep, even when a person has the chance to do so. This can affect a person’s sleep so much that they still feel tired after they wake up. The dangers of insomnia can affect more than just a person’s mood as people and if not treated properly can lead to other effects such as anxiety, depression, irritability, concentration problems, memory problems, poor immune system function, and reduced reaction time. There are 60 million Americans affected by the disease. About 25% of Americans experience acute insomnia each year with around 10% experiencing chronic insomnia.
Physician, Nursing and CMCN credits valid to December 1, 2022

Improving Patient Adherence and Quality of Life in Insomnia: Strategies for Managing Treatment Related Adverse Events Associated with Newer Therapies

Insomnia is a sleep disorder which makes it difficult to fall asleep or stay asleep, even when a person has the chance to do so. This can affect a person’s sleep so much that they still feel tired after they wake up. The dangers of insomnia can affect more than just a person’s mood as people and if not treated properly can lead to other effects such as anxiety, depression, irritability, concentration problems, memory problems, poor immune system function, and reduced reaction time. There are 60 million Americans affected by the disease. About 25% of Americans experience acute insomnia each year with around 10% experiencing chronic insomnia.
Physician, Nursing and CMCN credits valid to December 1, 2022

What Managed Care Needs to Know about New Therapies in the Management of Insomnia

Insomnia is a sleep disorder which makes it difficult to fall asleep or stay asleep, even when a person has the chance to do so. This can affect a person’s sleep so much that they still feel tired after they wake up. The dangers of insomnia can affect more than just a person’s mood as people and if not treated properly can lead to other effects such as anxiety, depression, irritability, concentration problems, memory problems, poor immune system function, and reduced reaction time. There are 60 million Americans affected by the disease. About 25% of Americans experience acute insomnia each year with around 10% experiencing chronic insomnia.
Physician, Nursing and CMCN credits valid to December 1, 2022

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  Diabetes, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Ophthalmology,  Pulmonary, Urology , Additional Topics

Ophthalmology

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  Diabetes, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Ophthalmology,  Pulmonary, Urology , Additional Topics

Pulmonary

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  Diabetes, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Ophthalmology,  Pulmonary, Urology , Additional Topics

Urology

Challenges and Opportunities in Overactive Bladder Care: A Framework to Optimize Outcomes

This activity is intended for urologists, primary care physicians, and obstetricians/gynecologists.
The goal of this activity is that learners will be better able to remain current on key evidence when making clinical decisions regarding the use of pharmacotherapy in the management of OAB.

Upon completion of this activity, participants will:

Have increased knowledge regarding the:

  • Burden of adverse effects associated with anticholinergic therapy in patients with OAB
  • Role of beta-3 adrenergic receptor agonists in the management of OAB
  • Unmet needs surrounding the pharmacoeconomics of medications used to treat OAB

Demonstrate greater confidence in their ability to:

  • Appropriately manage patients with OAB

Physician, Nursing and CMCN credits valid to September 29, 2023

Patient-Focused Treatment Decisions in the Management of Overactive Bladder (OAB): Expert Strategies for Improved Clinical and Economic Outcomes

Overactive bladder (OAB) is a highly prevalent condition that approximately 17% of women and 16% of men over 18 suffer from, that’s an estimated 33 million people; however, the numbers may be higher due to undiagnosed cases. OAB occurs about twice as frequently in women as in men, and while OAB is not considered a normal part of aging, it does become more prevalent with advanced age. OAB has a significant impact on quality of life (QoL), comorbidities and cost; sufferers are two to three times more likely to experience disturbed sleep, overeating, poor self-esteem, and depression. Despite its impact, OAB remains underdiagnosed and undertreated. Screening and evaluating patients is of utmost importance in order to improve diagnosis and patient QoL. Patients are uncomfortable bringing up the subject and it falls to the physicians to make sure the topic is broached occasionally, while sometimes a patient will deny it quickly the first time asked out of embarrassment, the second time they may have reflected and be ready to accept screening and treatment. This activity on overactive bladder will provide medical directors, practicing physicians and nurses with important information regarding the consequences and clinical, societal, and economic burden of underdiagnosed and mismanaged overactive bladder, available data around the optimal cost and efficacy data around treatments and their side-effects, payer challenges and strategies to achieve optimal cost management and strategies for individualized therapy and improved patient adherence.
Physician, Nursing and CMCN credits valid to March 1, 2023

 

Navigate to:  Preventive Health & Lifestyle Medicine | Behavioral Health | Chronic Illness: Autoimmune,  Cardiovascular,  Diabetes, Infectious Disease,  Musculoskeletal/Rheumatology,  Neurological,  Ophthalmology,  Pulmonary, Urology , Additional Topics

Additional Topics

Preparing for a New Era in Chronic Cough Management: Managed Care Considerations on the Role of New and Emerging Therapies is a two-part webinar series

Chronic cough, which is observed in approximately 12% of the US population, is defined as a cough that lasts for more than 8 weeks. Patients with chronic cough are often distressed by the condition, which can lead to depression, anxiety, a decline in quality of life, and changes to their social activities. The diagnosis and management of chronic cough can be challenging, with only approximately 50% of patients receiving a diagnosis. Recent advances have been made in the understanding and management of refractory chronic cough, with several novel therapies being evaluated in ongoing clinical studies.
Physician, Nursing and CMCN credits valid to June 1, 2023

Preparing for a New Era in Chronic Cough Management: Managed Care Considerations on the Role of New and Emerging Therapies

Chronic cough, which is observed in approximately 12% of the US population, is defined as a cough that lasts for more than 8 weeks. Patients with chronic cough are often distressed by the condition, which can lead to depression, anxiety, a decline in quality of life, and changes to their social activities. The diagnosis and management of chronic cough can be challenging, with only approximately 50% of patients receiving a diagnosis. Recent advances have been made in the understanding and management of refractory chronic cough, with several novel therapies being evaluated in ongoing clinical studies.
Physician, Nursing and CMCN credits valid to June 1, 2023

Preparing for a New Era in Chronic Cough Management: A Closer Look at the Role of New and Emerging Therapies

Chronic cough, which is observed in approximately 12% of the US population, is defined as a cough that lasts for more than 8 weeks. Patients with chronic cough are often distressed by the condition, which can lead to depression, anxiety, a decline in quality of life, and changes to their social activities. The diagnosis and management of chronic cough can be challenging, with only approximately 50% of patients receiving a diagnosis. Recent advances have been made in the understanding and management of refractory chronic cough, with several novel therapies being evaluated in ongoing clinical studies.
Physician, Nursing and CMCN credits valid to June 1, 2023

Copyright permissions

To the best of our knowledge permissions for use of any copyright materials was received by each individual presenter. NAMCP/AAMCN does receive permissions to record, transcribe and publish materials (slides and audio) from each speaker. These permissions are on file at NAMCP headquarters.

For more information contact Jeremy Williams at 804-527-1905 or jwilliams@namcp.org.
Disclaimer

NAMCP and or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.